000			04085nam a22004455i 4500
999			_c10011 _d10011
001			10011
003			ES-VaUE
005			20210528161458.0
006			a||||fo|||| 00| 0
007			cr nn 008mamaa
008			201208s2021 gw | o |||| 0|eng d
020			_a3030562670
024	7		_a10.1007/978-3-030-56267-0 _2doi
040			_bspa _dES-VaUE
050			_aRC280.T6 _b.W66 2021 EB
072		7	_aMMN _2bicssc
072		7	_aMED080000 _2bisacsh
072		7	_aMKR _2thema
082	0	4	_a616.07548 _223
245	1	0	_aLocoregional Radionuclide Cancer Therapy _bClinical and Scientific Aspects _cedited by Franklin C.L. Wong
250			_a1st ed. 2021
264		1	_aCham _bSpringer International Publishing _bImprint: Springer _c2021
300			_a1 online resource (XII, 268 p. 76 illus., 56 illus. in color.)
336			_atext _btxt [ _2rdacontent]
337			_acomputer _bc [ _2rdamedia]
338			_aonline resource _bcr [ _2rdacarrier]
505	0		_aHuman Cancer- Epidemiology, Hallmarks, and Defense Strategies -- Cancer Treatment Modalities Systemic and Loco regional Approaches: Challenges and Opportunities of multidisciplinary approaches -- Cancer Radiotherapy: General Considerations and Human Radiobiology -- Radionuclide Cancer Therapy- Unsealed Alpha, Beta and Gamma Emitters -- Locoregional Therapy – Cancer Interventions with and without Radionuclides -- Radiation Dosimetry Considerations of Locoregional Radionuclide Cancer Therapy -- Voxel-based Targeted Radionuclide Therapy Dosimetry -- Locoregional Unsealed Radionuclide Cancer Therapy – Experimental Findings -- Animal Cancer Therapy Models – Ready Translation to Humans -- An Overview of Regulations of Radiopharmaceuticals -- Locoregional Radionuclide Cancer Therapy (LRCT) Using Sealed & Unsealed Radionuclides
520			_aThis book reviews locoregional radionuclide cancer therapies (LRCT). Proving an increasingly viable alternative to radiotherapy, radionuclide therapy includes a diversity of choices of well characterized biochemical and physiologic target molecules. The delivery and retention of radionuclides may be monitored by advanced imaging for exact tissue localization and for real-time dosimetry to enable personalized precision medicine. Radiopharmaceuticals in human cancer therapies are typically delivered in systemic routes but can also be designed for locoregional routes to harness pharmacokinetic advantages of higher payload and lower systemic toxicities. This book explores the latest advancements and clinical considerations of the locoregional approach. Throughout the chapters, the clinical and scientific bases of cancer treatment and the locoregional use of radionculides are explored. Mathematical models of radiation dosimetry of locoregional radionculdies on tissues are studied using common models for multiple commercially available radionuclides. Rodent and canine tumor models of LRCT are compared for selected radionuclides and radiopharmaceuticals. The practical aspects of radiopharmaceuticals production, marketing, transport, as well as radiation protection are reviewed. Finally, the combination of LRCT with immunotherapy and other cancer therapies and prospective future use of LRCT are discussed. This is a guide for practicing nuclear physicians, interventional radiologists, radiation oncologists, radiation scientists, veterinarians and oncologists to expand their knowledge base and to prepare for designing locoregional radionuclide cancer therapies in animals and in humans
650		0	_aNuclear medicine
650		0	_aRadiology
650		0	_aInternal medicine
650	1	4	_aNuclear Medicine.
650	2	4	_aImaging / Radiology.
650	2	4	_aInternal Medicine.
700	1		_aWong, Franklin C.L., _eeditor _4edt _4http://id.loc.gov/vocabulary/relators/edt
776			_z3-030-56266-2
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-56267-0 _zAcceso a este recurso digital (usuarios Universidad Europea de Valencia)
942			_2lcc _cLE
998			_db